Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × donafenib × Clear all

Phase

Phase 3 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Cisplatin 50 Carboplatin 45 Radiotherapy 41 Paclitaxel 40 Docetaxel 38 Gemcitabine 33 Cyclophosphamide 32 Rituximab 29 Fluorouracil 26 Dexamethasone 25 Capecitabine 25 Doxorubicin 24 Prednisone 20 Bevacizumab 19 Oxaliplatin 17 Leucovorin 17 Vincristine 15 Etoposide 15 Cytarabine 15 pembrolizumab 13 Pemetrexed 13 Imatinib Mesylate 13 Drug Therapy 13 Zoledronic Acid 12 Radiosurgery 12 Irinotecan 12 Filgrastim 12 Erlotinib Hydrochloride 11 Surgical Procedures, Operative 10 Standard of Care 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡